PCSK9 and neoplasm: Analogous to the in vitro results, the Western blotting analysis of the collected primary tumor lysates revealed the significant downregulation of PCSK9 (OLE 73.5% versus 100% VC) and upregulation of LDLR in OLE-treated group versus VC-treated mouse tumors (OLE 114.3% versus 100% VC, Figure 8D,E).